The Marburg virus (MBGV) nucleocapsid complex is composed of four viral proteins (NP, L, VP35, and VP30) and the negative-strand nonsegmented genomic RNA. NP, L, and VP35 are functionally conserved among the order Mononegavirales, whereas VP30, a phosphoprotein, represents a filovirus-specific nucleocapsid protein. In the present paper, we have characterized the localization and function of VP30 phosphorylation. The main phosphorylation sites are represented by seven serine residues in the region of amino acid 40 to 51 of VP30. Additionally, trace amounts of phosphothreonine were detected. Substitution of serine residues 40 and 42 by alanine abolished the interaction of VP30 with NP-induced inclusion bodies, which contain nucleocapsid-like structures formed by NP. Substitution of the other phosphoserine residues had little effect on this interaction. Replacement of the introduced alanine residues 40 and 42 by aspartate restored the interaction between VP30 and the NP inclusions pointing to the importance of negative charges at these particular positions.
INTRODUCTION
Marburg virus (MBGV) and the closely related Ebola virus (EBOV) make up the family Filoviridae, which together with the Paramyxoviridae, Rhabdoviridae, and Bornaviridae constitutes the order Mononegavirales. Filoviruses are highly pathogenic for humans and nonhuman primates, causing a severe hemorrhagic fever with high fatality rates (for reviews see Martini and Siegert, 1971; Pattyn, 1978) . The emerging potential of filoviruses is underlined by several outbreaks during the last 6 years (WHO, 1995 (WHO, , 1999 (WHO, , 2001 . Several attempts have been made to detect the natural reservoir of filoviruses with hitherto no success (Breman et al., 1999; Leirs et al., 1999) . The prototype of Filoviridae, MBGV, was isolated in 1967, when several laboratory workers were infected after contact with imported monkeys (Siegert et al., 1967) .
The enveloped MBGV particles are composed of seven structural proteins and the RNA genome. Four viral proteins are the components of the nucleocapsid: the nucleoprotein NP Kolesnikova et al., 2000; Lötfering et al., 1999; Sanchez et al., 1992) , the L protein (Mühlberger et al., 1992) , VP35 , and VP30 . VP40 and VP24 are located between the envelope and the nucleocapsid and probably represent viral matrix proteins . The envelope of MBGV is decorated by the only surface protein, GP, which is inserted into the viral membrane as a homotrimer (Feldmann et al., 1991) . Since GP is the only surface protein of MBGV, it is assumed to be responsible for virus entry into host cells and to be the major target for the immune response of the infected organism. Thus, it has been shown for MBGV and EBOV that immunization against the respective surface protein was sufficient to protect guinea pigs and monkeys for a challenge infection (Hevey et al., 1998; Sullivan et al., 2000) .
MBGV infection of target cells is characterized by the formation of typical inclusion bodies which contain the nucleocapsid proteins . Formation of the inclusion bodies is induced by the major nucleocapsid protein, NP, which forms nucleocapsid-like tubular structures resembling the core structure of nucleocapsids in MBGV-infected cells (Kolesnikova et al., 2000) . It was further shown that NP is the central player in complex formation between the nucleocapsid proteins. NP interacts with itself and VP35 and builds a trimeric complex with L via VP35. Additionally, NP was found to interact with VP30 .
VP30 is encoded by the fifth gene of MBGV, which is placed between the GP gene and the gene coding for VP24 (MBGV gene order: 3Ј-NP-VP35-VP40-GP-VP30-VP24-L-5Ј). This genome organization is unusual since most viruses of the order Mononegavirales encode their nucleocapsid proteins by the first (NP or N), second (P), and last gene (L). The VP30 gene is 1249 nt in length and codes for a protein of 281 amino acids. VP30, as its EBOV 1 To whom correspondence and reprint requests should be addressed at Institut für Virologie der Philipps-Universität Marburg, Robert-Koch-Str. 17, 35037 Marburg, Germany. Fax: ϩϩ6421-2865482. Email: becker@mailer.uni-marburg.de. counterpart, is a phosphoprotein Elliott et al., 1985) .
The role of phosphorylation in the regulation of essential functions of cellular proteins by the reversible attachment of negative charges is well established. Also, many viruses exploit cellular protein kinases and phosphatases to regulate the function of their own proteins. In this paper, we have determined the localization of the phosphorylation sites of MBGV VP30. Subsequently, we have characterized the function of VP30 phosphorylation for the formation of the VP30/NP complex.
RESULTS

Treatment of VP30 with alkaline phosphatase
Recently, we have shown that MBGV VP30 is phosphorylated . As a first approach to further characterize this posttranslational modification, we investigated whether (i) the phosphorylation was sensitive to alkaline phosphatase (CIP) and, if so, whether (ii) phosphorylated and dephosphorylated VP30 displayed a different migration pattern in SDS-PAGE. To this end, MBGV particles were purified from the supernatant of MBGV-infected C1008 cells which were previously metabolically labeled with either [ 32 P i ] or [ 35 S]Promix. Isolated particles were treated with 1% SDS and boiled, and VP30 was immunoprecipitated from the lysates. The immune complexes were incubated with CIP to remove the attached phosphate groups and were finally separated on SDS-PAGE. The gels were dried and the radioactive signals were visualized using a Bio-Imager. 32 P-labeled VP30 migrated at 34 kDa as a relatively diffuse band (Fig. 1, lane 4) . CIP treatment resulted in an almost complete disappearance of the radioactive signal, demonstrating that most of the incorporated phosphate groups were sensitive to phosphatase (Fig. 1,  lanes 3 and 4) . A faint remaining signal in the CIP-treated sample migrated at 33 kDa (lane 3). The [ 35 S]Promixlabeled VP30 migrated in SDS-PAGE as a diffuse band at 33-35 kDa (lane 1). After digestion with CIP, the diffuse band disappeared and two discrete bands at approximately 33 and 35 kDa were detectable (lane 2). These bands were also faintly visible in the nontreated sample (lane 1, arrows). Quantification of the signal strengths of the upper and lower bands revealed that the ratio between the two signals was changed after dephosphorylation. In comparison to the 35kDa band, the signal of the lower band became stronger (quantification not shown). It is concluded that (i) phosphorylation of VP30 leads to a slightly altered migration of the protein in SDS-PAGE and (ii) additional to the phosphorylated VP30, nonphosphorylated VP30, is incorporated into the virions. The nature of the 35-kDa form is still unknown.
To investigate whether the recombinant VP30 was phosphorylated as well, the protein was expressed in HeLa cells using the vaccinia virus-T7 system. HeLa cells were infected with MVA-T7 and subsequently transfected with pGEM-VP30, a plasmid encoding VP30 under the control of the T7 promoter. At 8-12 h p.i., cells were metabolically labeled with [ 32 P i ] or [ 35 S]Promix, and VP30 was immunoprecipitated using a guinea pig anti-VP30 antiserum. Immune complexes were incubated with CIP and further treated and detected as described above. Figure 1 shows that [ 32 P i ]-and [ 35 S]Promix-labeled VP30 appeared as a diffuse band migrating at 33-34 kDa (lanes 5-8). Dephosphorylation of the 32 P ilabeled recombinant VP30 led to the removal of phosphate groups which is demonstrated by the reduced strength of the radioactive signal and the molecular weight shift of the protein to 33 kDa (lane 7). However, the dephosphorylation was not complete (Fig. 1, lanes 7 and 8) . Taken together, the recombinant VP30 is phosphorylated similar to the virion-associated VP30 and was, thus, available for further analysis.
Phosphoamino acid analysis
The type of phosphoamino acids within VP30 was determined using 2D thin-layer chromatography electrophoresis. Either virion-associated or recombinant VP30 was metabolically labeled with 32 P i , immunoprecipitated, and partially hydrolyzed with hydrochloric acid. The hydrolysates were mixed with standard phosphoamino acids, spotted onto thin layer plates, and electrophoresed in two dimensions (Fig. 2) . Quantification of the radioactive signals and comparison with the ninhydrine signals of the standard phosphoamino acids revealed the strongest signal for phosphoserine, which was accompanied by a small amount of phosphothreonine. The ratio between phosphoserine and phosphothreonine was 26:1 for the recombinant VP30 (left). This ratio was deter- C1008 cells were infected with MBGV and metabolically labeled with [ 32 P i ] or [ 35 S]Promix at 4 days p.i. Virions were purified from the supernatant of the cells and treated with 1% SDS. VP30 was immunoprecipitated from the lysate using a guinea pig anti-VP30 antiserum (dilution 1:250) and either treated with CIP or left untreated (Ϫ). The samples were separated by SDS-PAGE and gels were dried and exposed to BioImager plates. Recombinant VP30 (right, lanes 5-12): 5 ϫ 10 5 subconfluent HeLa cells were infected with MVA-T7 and subsequently transfected with 1 g of the plasmid pGEM-VP30. At 14-16 h p.i., cells were metabolically labeled with either [ 32 P i ] or [ 35 S]Promix, and VP30 was immunoprecipitated and treated as described above. MBGV, virion-associated VP30; VP30, recombinant VP30 immunoprecipitated from HeLa cell lysates; MVA-T7, HeLa cells infected with MVA-T7; Mock, HeLa cells, mock-infected; (ϩ), CIP-treated; (Ϫ), not treated with CIP. mined to be 10:1 for the virion-associated VP30 (right). This shift toward phosphothreonine might suggest that a special form of phosphorylated VP30 is favored for incorporation into progeny virions. Investigations to clarify this question are underway.
Formic acid treatment: N-terminal phosphorylation
It was then of interest to localize the phosphorylation site(s) in VP30. At first, the FLAG-tagged VP30 was expressed using the vaccinia virus-T7 system as described above, metabolically labeled with [ 32 P i ] or [ 35 S]Promix, immunoprecipitated, and treated with formic acid to cleave the protein between aspartate 89 and proline 90, the only site of VP30 where cleavage could take place at pH 2.5. Proteolytic fragments were separated on SDS-PAGE, and radioactive signals were visualized using a BioImager. Since only the N-terminal fragment of VP30 was labeled with 32 P i , it was suggested that VP30 is mainly phosphorylated in the 89 amino acids of the N-terminus (data not shown).
Phosphorylation state analysis of VP30 deletion mutants
To determine the localization of phosphate acceptor sites in VP30 more precisely, N-and C-terminal deletion mutants of VP30 were constructed dividing the molecule in two halves. At first a deletion mutant of VP30 was analyzed encompassing amino acids 152-281. However, this mutant turned out to be unstable upon expression in HeLa cells. Thus, a fusion protein was constructed containing the FLAG-tagged 500 N-terminal amino acids of the MBGV L protein fused to the C-terminus of VP30 ( Fig.  3A , L N-term /VP30 152-281 ). To verify that the N-terminus of L on one hand was not phosphorylated and on the other hand did not prevent phosphorylation of the fused fragment, additional mutants were constructed, expressing either the L N-terminus (L Nterm ) alone or the L N-terminus fused to the full-length VP30 (L Nterm /VP30 1-281 ). The mutants were expressed in HeLa cells using the vaccinia virus-T7 system, metabolically labeled with [ 32 P i ] or [ 35 S]Promix, immunoprecipitated, and separated by SDS-PAGE. The radioactive signals were visualized with a BioImager and quantified using the Raytest TINA software. Phosphorylation state analysis of these mutants showed that, as expected, the N-terminus of L was neither phosphorylated nor inhibitory for the phosphorylation of the fused full-length VP30 (data not shown). Examination of the mutant which contained the C-terminus of VP30 fused to the L N-terminus (L N-term /VP30 151-281 ) revealed that this protein was not phosphorylated (data not shown). These data underlined the previous findings that phosphorylation of VP30 did not take place in the C-terminus.
To further narrow down the phosphorylated site(s) in the N-terminus, deletion mutants of VP30 were constructed dividing the region of amino acid 1-151 ( Fig. 3A , VP30 1-40 , VP30 1-67 , VP30 1-151 , and VP30 68-151 ). The mutants and VP30 wild-type were expressed in HeLa cells using the vaccinia virus-T7 system as described above. Phosphorylation state analysis revealed that the full-length VP30 and the N-terminal mutant (VP30 1-151 ) were phosphorylated ( Fig. 3B, lanes 5-8) . The mutant containing only amino acids 68-151 was not phosphorylated pointing to amino acids 1-67 as the main phosphorylated region (Fig. 3B, lanes 9 and 10) . This was further underlined by the analysis of the mutants VP30 1-40 and VP30 1-67 . Quantification of the radioactive signals of the FIG. 2. Phosphoamino acid analysis of VP30. Virion-associated (MBGV, right) or recombinant VP30 (VP30, left) was metabolically labeled and purified as described under Fig. 1 . Immune complexes were separated by SDS-PAGE and blotted onto Immobilon membrane and the VP30-specific band was cut out. The protein was partially hydrolyzed with hydrochloric acid and resuspended in a mixture of standard phosphoamino acids. The sample was then spotted onto thin-layer plates and chromatographed in two dimensions. Plates were subsequently sprayed with ninhydrine solution, and the positions of the standard phosphoamino acids were marked. The plates were then exposed to a BioImager plate to detect the radioactive phosphoamino acids. VP30, recombinant VP30 purified from MVA-infected and transfected HeLa cells; MVA-T7; MVA-infected HeLa cells; MBGV, VP30 purified from MBGV structural proteins; PS, phosphoserine; PT, phosphothreonine; PY, phosphotyrosine. 32 P i -labeled proteins, which were normalized by the [ 35 S]Promix-labeled expression control, showed that the first 67 amino acids contained almost the whole phosphor label of VP30 (Fig. 3C, lanes 1 and 2) , whereas the phosphorylation of VP30 1-40 was greatly reduced (6% of the mutant VP30 1-67 , Fig. 3C, lanes 3 and 4) .
Taken together, these experiments demonstrated that the main phosphorylation sites of VP30 were located in the N-terminus between amino acid 40 and 67. Thus, the following analyses focused on this region.
Substitution mutants of serine residues in the region of amino acid 40 to 67
Sequence analysis of VP30 revealed seven serine residues in the region of amino acid 40-67 which were FIG. 3. Phosphorylation state analysis of VP30 deletion mutants. (A) Schematic representation of the employed VP30 mutants. The numbers in subscript refer to the amino acids of VP30 present in the respective mutant. At the right-hand side, the phosphorylation state of the respective mutant is indicated. (B) and (C) Phosphorylation state of VP30 deletion mutants. 5 ϫ 10 5 HeLa cells were infected with MVA-T7 and transfected with 1 g of the respective plasmids encoding either VP30 wild-type or VP30 deletion mutants. Cells were metabolically labeled as described under Fig. 1 , and VP30 and the VP30 mutants were immunoprecipitated using a guinea pig anti-VP30 antiserum (dilution 1:250) and protein A-Sepharose. Immune complexes were separated on SDS-PAGE; gels were dried and exposed to a BioImager plate. S, [ 35 S]Promix-labeled VP30; P, 32 P i -labeled VP30. clustered between amino acids 40 and 51 ( Fig. 4 , above lane 1). We constructed a set of FLAG-tagged full-length mutants of VP30 by substituting groups of serine residues with alanine residues (Fig. 4) . The mutants were expressed using the vaccinia virus-T7 system, metabolically labeled, immunoprecipitated, separated by SDS-PAGE, and analyzed using a BioImager as described above. Metabolic labeling of the mutants with [ 35 S]Promix was used to normalize the signals of 32 P i labeling (not shown). When all of the seven serine residues in the amino acid region 40 to 51 were changed to alanine, the radioactive signal was decreased by 80% compared to the wild-type of VP30 (Fig. 4, lanes 1 and 2) . Substitution of the serine residues in the region 40-46 or in the region 47-51 to alanine resulted in both cases in a reduction of the signal strength to approximately 50% (Fig. 4 , lanes 3 and 4). Substitution of three serines at positions 43, 46, and 51, which are located in conserved protein kinase recognition sites, lowered the phosphorylation signal by 30% compared with the wild-type (Fig. 4, lanes 1 and 5) . These results point to the fact that most if not all of the serine residues in the amino acid region 40-51 were targets for cellular kinases.
Functional significance of the phosphorylation of serine residues 40 and 42
It was shown previously that MBGV VP30 interacted with the major nucleocapsid protein NP . NP is the main determinant of the nucleocapsid complex which forms, upon recombinant expression, intracellular inclusions. These inclusions contain accumulated tubular structures which resemble the core nucleocapsids formed in the cytoplasm of MBGV-infected cells (Kolesnikova et al., 2000) . When coexpressed with NP, the otherwise homogeneously distributed VP30 is redistributed into the NP-induced inclusions . It was of interest whether the phosphorylation of VP30 might have an impact on this protein-protein interaction. VP30 or phosphorylation-deficient VP30 mutants were, thus, coexpressed together with NP using the vaccinia virus-T7 system and cells were subjected to immunofluorescence analysis.
As expected, VP30 wild-type colocalized with NP in the NP-induced inclusion bodies when the two proteins were coexpressed ( Fig. 5A ; Becker et al., 1998) . Coexpression of the mutants VP30 S40-51A or VP30 S40-46A with NP, however, showed a different pattern. Whereas NP is still found in the inclusion bodies, VP30 is now homogeneously distributed and, in some cells, concentrated around the inclusion bodies (Figs. 5B and 5C). Two other mutants, VP30 S47-51A and VP30 S43,46,51A , showed the wildtype pattern when coexpressed with NP (Figs. 5D and 5E). Since the latter two mutants had in common that they both contained serine residues at positions 40 and 42, it was presumed that possibly these two residues were particularly critical for the interaction with NP inside the inclusions. Therefore, VP30 mutants were constructed where the serine residues at position 40 and 42 were either separately or together substituted by alanine (VP30 S40A , VP30 S42A , and VP30 S40,42A ). Phosphorylation state analysis of the mutant VP30 S40,42A , with both serines replaced by alanine, showed a reduction of the phosphorylation by approximately 40% (not shown). When either serine 40 or serine 42 was replaced, phosphorylation of the respective mutants was only slightly impaired (not shown). These results suggested that the two serine residues could alternatively be phosphorylated and only the replacement of both impaired the overall phosphorylation of VP30. To investigate the effect of the missing serine residues at amino acid position 40 and/or 42 on the interaction with NP, the three mutants were coexpressed together with NP using the vaccinia virus-T7 system as described above and subjected to immunofluorescence analyses (Figs. 5F-5H). It is shown that the exchange of serines 40 and 42 obviously blocked the redistribution of VP30 into the NP-induced inclusions (Fig. 5F ). Substitution of either serine 40 or 42 alone only partly inhibited the interaction with NP (Figs. 5G and 5H). The respective mutants VP30 S40A and VP30 S42A are predominantly located inside or at the rim of the inclusions and, to a lesser extent, distributed homogeneously in the cytosol. It is therefore concluded that serine residues 40 and 42 together are essential for the interaction between NP inclusions and VP30.
Since the altered phenotype of the mutant VP30 S40,42A
FIG. 4. Phosphorylation state analysis of amino acid region 40-51 in VP30. 5 ϫ 10 5 subconfluent HeLa cells were infected with MVA-T7 and transfected with 1 g of each plasmid encoding VP30 wild-type or VP30 substitution mutants which contained serine-to-alanine exchanges in the amino acid region 40-51. Cells were metabolically labeled with [ 32 P i ], and VP30 and the VP30 mutants were immunoprecipitated using a guinea pig anti-VP30 antiserum (dilution 1:250) and protein A-Sepharose. Immune complexes were separated by SDS-PAGE and gels were exposed to a BioImager plate. The amino acid sequence of VP30 (40-51) is given above lane 1. For the mutants, only the respective serine to alanine substitutions are indicated.
could have been the result of the missing serine residues rather then the missing phosphorylation of the amino acids, we mimicked the negative charges of the phosphate groups at serines 40 and 42 by replacing the two amino acids either singly or in combination to aspartate ( Figs. 5I-5K ). When single aspartates were introduced, the other serine residue was changed to alanine. It was found that, indeed, substitution of amino acids 40 and 42 to aspartate revealed almost the same distribution pattern as the VP30 wild-type (Fig. 5I) . The substitution of only one of the serines residues, either S 40 or S 42 , by aspartate was not sufficient to support the redistribution of VP30 into the inclusions (Figs. 5J and 5K) . These results emphasize the importance of negative charges at amino acid position 40 and 42 for the interaction of VP30 with the NP-induced nucleocapsid-like structures.
Immunoelectron microscopy
Finally, the distribution of VP30 wild-type and one of the mutants which was unable to interact with the NP inclusions (VP30 S40,42A ) were analyzed by immunoelectron microscopy to confirm the colocalization of VP30 wildtype and NP inside the inclusions and to investigate the localization of the mutant. VP30 or the mutant VP30 S40,42A , both containing FLAG epitopes at the N-terminus, were expressed in HeLa cells together with NP as described above. The cells were harvested at 16 h p.i. and cell pellets were embedded in LR gold for immunogold labeling. Subsequently, ultrathin sections were prepared which were used for immunostaining. VP30 and VP30 S40,42A were labeled with gold particles of a diameter of 10 nm, and NP was labeled with 6-nm gold particles. Figure 6A shows a part of an inclusion in cells expressing VP30 and NP. Both proteins colocalized inside the inclusion (black arrows: VP30, arrowheads: NP). Inclusion bodies in cells expressing NP and VP30 S40,42A , however, showed a different pattern. Here, VP30 S40,42A (black arrows) was detected primarily homogeneously in the cytoplasm (not shown) or at the periphery of the inclusions, suggesting that VP30 S40,42A is targeted to the inclu-FIG. 5. Influence of serine residues 40-51 on colocalization of VP30 and NP inclusions. HeLa cells were infected with MVA-T7 and cotransfected with plasmids encoding the FLAG-tagged VP30 wild-type or the FLAG-tagged VP30 substitution mutants together with 100 ng of pT-NP, encoding NP of MBGV. The transfected amounts of the plasmids encoding VP30 mutants was varied according to the expression rates of the respective mutants. pTM-VP30, 10 ng; pTM-VP30 S40-51A , 40 ng; pTM-VP30 S40-46A , 40 ng; pTM-VP30 S47-51A , 400 ng; pTM-VP30 S43,46,51A , 400 ng. VP30 mutants in F to K: 100 ng. At 16 h p.i., cells were fixed with 3% PFA and permeabilized using 0.2% Triton X-100. Subsequently, cells were subjected to immunofluorescence analysis using a mouse monoclonal anti-NP antibody (dilution 1:25) and a rabbit anti-FLAG serum (Zymed, dilution 1:50). Bound antibodies were detected with a FITC-labeled donkey anti-rabbit serum (Dianova, dilution 1:100) and a rhodamine-labeled goat anti-mouse serum (Dianova, dilution 1:100). sion but could not interact with the NP inside (arrowheads, Fig. 6B ).
DISCUSSION
In the present paper, we have characterized the localization and function of the phosphorylation of MBGV VP30. In contrast to EBOV VP30, which acts as an EBOVspecific transcription activator, MBGV VP30 is not essential for viral transcription . Although MBGV VP30 was able to partially replace EBOV VP30 in its function to activate EBOV transcription, the role of MBGV VP30 in the homologous system remains obscure .
We earlier presented evidence that VP30 is a phosphoprotein , and we have shown here that the major phosphorylation sites of VP30 are represented by seven serine residues in the region of amino acids 40 to 51 whose exchange to alanine reduced the phosphorylation of VP30 by 80%. The remaining phosphorylation of this mutant is most probably caused by phosphothreonine, which is suggested by the performed phosphoamino acid analysis. The exact localization of this phosphothreonine residue(s) is not yet determined.
The phosphoserines in amino acid region 40 to 51 are only partly located in conserved recognition sites of known protein kinases. Serine 43 is located in a conserved protein kinase C site, serine 46 in a protein kinase CKII site, and serine 51 might be suitable for a proline-dependent kinase similar to the mitogen-activated protein kinases (Davis, 1993) . Exchange of these three serines to alanines decreased the phosphorylation of VP30 only by 30%. Thus, our data point to additional unidentified protein kinases with different recognition motifs which are involved in VP30 phosphorylation. Substitution of serine residues 40-46 or 47-51 to alanine reduced the phosphorylation of VP30 by approximately 50%, respectively, showing that serine residues of the whole region might be targets for protein kinases. This is further supported by computer-based analysis, which predicted with high-probability values (Ͼ0.9, data not shown) that all serine residues 40, 42, 43, 46, 47, 50 , and 51 might act as phosphate acceptor sites (Program Net-Phos II, Blom et al., 1999) .
Multisite phosphorylation, as it takes place with VP30, has also been detected in MBGV NP and several other viral and cellular proteins (Lötfering et al., 1999 , for review see Cohen, 2000) . Phosphorylation of different ac-FIG. 6. Immunoelectron microscopic analysis of the interaction between VP30 and NP inside the inclusions. 1.5 ϫ 10 6 subconfluent HeLa cells were infected with MVA-T7 and cotransfected with plasmids encoding the FLAG-tagged VP30 wild-type (250 ng) or FLAG-tagged VP30 S40,42A (250 ng) together with pTM-NP (2.5 g) encoding NP of MBGV. At 16 h p.i., cells were fixed with 3% PFA and further processed for electron microscopy. Ultrathin sections of the cells were incubated with a 1:100 dilution of rabbit serum against the FLAG epitope and a 1:10 dilution of a mouse monoclonal antibody against NP. Subsequently, sections were incubated with a 1:30 dilution of gold-labeled anti-mouse (6-nm gold particles) and gold-labeled anti-rabbit (10-nm gold particles) antibodies. (A) Cells transfected with VP30 wild-type and NP. (B) Cells transfected with VP30 S40,42A and NP. Bar, 100 nm. ceptor sites might have an antagonistic effect, as it was shown for the activation of cdc2 (Hoffmann et al., 1993) . In other cases, such as the MAPKAP kinase-2, cooperative phosphorylation of multiple acceptor sites was the prerequisite for a fully active protein (Ben-Levy et al., 1995) . Multiple phosphorylation has also been observed for the P protein of VSV, the cofactor of the viral polymerase L. The sequential phosphorylation by two cellular protein kinases was necessary to fully phosphorylate the protein. Phosphorylation by protein kinase CKII was essential for the multimerization of P and its function in viral transcription. The subsequent phosphorylation occurring in the C-terminus is discussed to regulate viral replication (Gao and Lenard, 1995) .
We have previously described that intracellular interaction between VP30 and NP resulted in the relocalization of the otherwise homogeneously distributed VP30 into NP-induced inclusions . In the present paper we were able to show that this relocalization of VP30 is dependent on negative charges at amino acid positions 40 and 42, which are represented by phosphoserines. Exchange of these two serine residues to alanine residues destroyed the interaction between VP30 and NP inside the NP-induced inclusions. Replacing the introduced alanine residues with the negatively charged aspartate restored the interaction between VP30 and NP, and VP30 was again found within the inclusions. It is therefore concluded that rather the phosphorylation of the amino acids at position 40 and 42 and not the serine residues themselves are critical for the redistribution of VP30 into the NP-induced inclusions. The more C-terminally located serine residues (amino acid position 43, 46, 47, 50, and 51) , which are also subjected to phosphorylation, seemed to be less important for this particular function.
NP inside the inclusions is organized in tightly packed helical nucleocapsid-like structures. In electron microscopic analysis, the NP helices appeared either as hexagonally arranged circles (cross section), or as tubularlike structures (longitudinal section), or, more often, as a reticular network (skewed section) (Kolesnikova et al., 2000) . It is presumed that these NP helices, which can also be detected in MBGV-infected cells, represent the precursors of mature nucleocapsids. These are assembled by recruiting additional viral proteins, i.e., the other nucleocapsid proteins (VP30, VP35, and L), and possibly the matrix proteins VP40 and VP24. Consequently, the electron density of the nucleocapsids is increased. The mature nucleocapsids which are characterized by their high electron density (Kolesnikova et al., 2000) are presumed to be released from the inclusions, transported to the cell surface, and enwrapped with a lipid bilayer consisting of the plasma membrane with the inserted viral surface protein GP. In this scenario, the redistribution of VP30 into the NP-induced inclusions which was observed upon coexpression of NP and VP30 most likely reflects the interaction of the protein with NP helices. This interaction corresponds to the nucleocapsid maturation in MBGV-infected cells. It is thus concluded that one prerequisite for the maturation of MBGV nucleocapsids is the phosphorylation of serine residues 40 and 42 of VP30.
The only other viruses in the order Mononegavirales containing a structural protein of similar characteristics as filoviral VP30 (i.e., extra nucleocapsid protein, interaction with the nucleoprotein) belong to the pneumovirinae subfamily of Paramyxoviridae. Here, M2-1 represents an additional nucleocapsid protein besides N, P, and L, which are conserved among the order Mononegavirales. M2-1 has been shown to interact with the nucleoprotein of respiratory syncytial virus in intracellular inclusions and to act as a transcription elongation and an antitermination factor (Collins et al., 1996; Garcia et al., 1993; Hardy and Wertz, 1998) . Recently, Hardy and Wertz found that M2-1 is a phosphoprotein (Hardy and Wertz, 2000) . As with MBGV VP30, two forms of M2-1 were identified, differing in migration velocity in SDS-PAGE. The phosphorylation sites within M2-1 have been localized to the N-terminus where phosphoserine and phosphothreonine were detected (Cuesta et al., 2000) . The phosphorylation seemed to influence the RNA-binding specificity of M2-1 (Cuesta et al., 2000) . The function of phosphorylation for the binding of M2-1 to N has not been investigated.
Phosphorylation has previously been shown to be important for the assembly of the nucleocapsid complex of measles virus. Gombart et al. (1995) showed that the nucleoprotein of measles virus which is assembled into the nucleocapsids contains additional phosphoserine residues compared to the nonassembled protein. This result led to the conclusion that this additional phosphorylation might be essential for the incorporation of the nucleoprotein into measles virus nucleocapsids.
By phosphatase treatment of virion-associated VP30 it was found that in addition to the majority of phosphorylated VP30, trace amounts of non-or weakly phosphorylated VP30 were incorporated into the virions. Since our data suggested that only phosphorylated VP30 is able to be incorporated into progeny virus, it is unclear how these molecules were bound to the virions. The presence of these molecules inside the virions could have several reasons. Recently, we have found that VP30 is able to build homooligomers whose formation is independent of the phosphorylation state of the protein (unpublished data). Thus, it is possible that nonphosphorylated VP30 molecules are incorporated into the progeny virions via oligomerization with phosphorylated molecules.
Taken together, we have provided evidence that the phosphorylation of VP30 takes place predominantly at serine residues in the amino acid region 40-51. The phosphorylation of serine residues 40 and 42 is essential for the interaction of the protein with the aggregates of NP, which are built of nucleocapsid-like particles. This interaction is presumed to stand for one step in the maturation of the MBGV nucleocapsid.
MATERIALS AND METHODS
Viruses and cell lines
C1008 cells, a cloned cell line of Vero cells (ATCC CRL 1586), Vero cells, and HeLa cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum. The Musoke strain of MBGV isolated in 1980 in Kenya (Smith et al., 1982) was propagated in C1008 cells and purified as described previously (Funke et al., 1995) . Monolayer cultures of HeLa cells were used for all experiments with the recombinant vaccinia virus MVA-T7 containing the T7 RNA-polymerase gene (Sutter et al., 1995) . MVA-T7 was grown and titered in chicken embryo fibroblasts. For all transfections, HeLa cells were grown in six-well plates (7 cm 2 ) using DMEM containing 10% fetal calf serum.
Purification of 32 P-labeled MBGV Propagation, labeling, and purification of MBGV was essentially done as described previously (Becker et al., 1994) , with the exception that the purification was carried out in the presence of 1 mM phenylmethylsulfonyl fluoride (PMSF), 50 mM sodium fluoride (NaF), and 100 M sodium-o-vanadate (NaV).
Molecular cloning of VP30 and VP30 mutants
For the expression of VP30 and the VP30 mutants, the plasmids pGEM3zfϩ (Promega) and pTM1 (Fuerst et al., 1986) were used. In both plasmids, the inserted genes are under the control of the T7 promoter.
Cloning of pGEM-VP30. The genomic RNA of MBGV, which was used as template for reverse transcriptionpolymerase chain reaction (PCR), was purified as described previously (Mühlberger et al., 1992) . The open reading frame of VP30 was amplified by reverse transcription-PCR using the primers 100 (5Ј GAC GGA TCC AAA ATG CAA CAA CCT CGC GGA AGA AGT CGA 3Ј) and 56 (5Ј GAC GGA TCC AGA GGT ACA AGT TGT TAA TTA GAC ACT TAG 3Ј), each containing a BamHI restriction site (underlined). The resulting DNA fragment contained the sequence of the VP30 gene from nucleotide 8863-9983 of the MBGV RNA (EMBL data bank Accession No. Z12132). The PCR fragment was gel purified, cut with BamHI, and cloned into the BamHI site of the vectors pGEM3zfϩ and pTM1. The final plasmids were verified by sequencing and designated as pGEM-VP30 and pTM-VP30.
Cloning of the N-and C-terminal deletion mutants of VP30. The mutants were constructed according to standard molecular biological techniques using pGEM-VP30 as template (digestion with suitable restriction endonucleases, Klenow fill-in, or S1-nuclease digestion, relegation) (Lötfering et al., 1999) .
Cloning of the mutant pGEM-VP30 .The coding region for amino acid 69-151 was amplified by PCR using pGEM-VP30 as template. The forward primer contained a KpnI restriction site followed by the nucleotides 9067-9087 of VP30 sequence. The reverse primer contained a BamHI site joined to the VP30 sequence 9292-9318. The PCR fragment was cloned into the plasmid pGEM3zfϩ.
Cloning of pTM-VP30 FLAG and the VP30 substitution mutants. pTM-VP30 FLAG was constructed using pTM-VP30 as template by amplifying the open reading frame of VP30 via PCR. The forward primer contained an NcoI restriction site followed by the first 20 nucleotides of the VP30 open reading frame. The reverse primer contained a BamHI restriction site followed by the sequence encoding the FLAG epitope joined to the last 20 nucleotides of the open reading frame of VP30. The PCR product was digested with BamHI and NcoI and cloned into the vector pTM1. The influence of the FLAG epitope on the intracellular localization of VP30 was checked by immunofluorescence analysis revealing that the distribution of VP30 and VP30 FLAG were identical (data not shown).
Cloning of the VP30 substitution mutants with exchanged serine residues in the amino acid region 40-51 was performed using either the Quick Change site-directed mutagenesis kit (Stratagene) or the Transformer Site-directed Mutagenesis kit (Clontech). Exchange of serine residues was performed either in a single step if neighboring residues were to be replaced (e.g., S 40 and S 42 ) or in sequential steps if more than two serine residues at more distant locations had to be exchanged. As template, pTM-VP30 FLAG was used.
Infection and transfection of HeLa cells
For phosphorylation state and phosphoamino acid analyses, subconfluent HeLa cells (5 ϫ 10 5 cells in 7-cm 2 wells) were infected with a multiplicity of infection of 3-5 plaque-forming units MVA-T7 per cell. At 1 h postinfection, cells were transfected with the respective plasmids encoding NP, VP30, or VP30 mutants using the lipofectin precipitation method (Felgner et al., 1994) . The amounts of plasmid DNA which were transfected are given in the figure legends.
Metabolic labeling with [ 32 P]orthophosphate or [ 35 S]Promix
At 14 h posttransfection, HeLa cells were starved for 1 h with methionine-and cysteine-deficient DMEM or phosphate-deficient Eagle's minimum essential medium. Medium was removed, and cells were labeled for 2 h with 25 Ci of [ 35 S]Promix (Amersham) or 3 h with 167 Ci of [ 32 P i ] (Amersham) in 1 ml starvation medium.
Immunoprecipitation and digestion with alkaline phosphatase
After metabolic labeling, the medium was removed, and cells were washed twice with ice-cold PBS supplemented with 1 mM PMSF, 50 mM NaF, and 100 M NaV.
To determine the phosphorylation state of individual VP30 mutants, 5 ϫ 10 5 labeled cells were scraped into 0.5 ml ice-cold CoIP buffer [20 mM Tris-HCl, pH 7.5, 100 mM sodium chloride, 0.4% (w/v) deoxycholic acid, 1% (w/v) NP-40, 25 mM iodoacetamide, 1 mM PMSF, 50 mM NaF, 100 M NaV, 17.5 mM EDTA]. Subsequently, cells were sonicated, and cell debris was removed by centrifugation for 5 min at 13,000 rpm. The supernatant was incubated for 1 h at 4°C with 30 l protein A-Sepharose, which had been equilibrated in CoIP buffer. Sepharose beads were precipitated at 13,000 rpm for 1 min at 4°C in a tabletop centrifuge, and supernatants were further incubated for 1 h with 2 l of a polyclonal guinea pig antiserum raised against MBGV VP30, or 1 l mouse monoclonal anti-FLAG M2 antibody (Sigma). Immune complexes were bound to 25 l protein A-Sepharose during 1 h at 4°C, precipitated, and washed five times with ice-cold CoIP buffer. Final pellets were resuspended in 50 l of sample buffer [50 mM Tris-HCl, pH 6.8, 4% (w/v) sodium dodecyl sulfate (SDS), 12% (w/v) glycerol, 0.1 M dithiothreitol, 0.01% (w/v) saturated bromphenol blue solution] and incubated for 5 min at 95°C. Ten microliters of [ 32 P i ]-or 20 l of [ 35 S]Promix-labeled samples were subjected to SDS-PAGE. The radioactive signals were visualized by exposing the dried gels to a BioImager plate and quantified using the BioImaging Analyzer Fuji BAS-1000 with the Raytest TINA software.
For alkaline phosphatase treatment, immune complexes bound to Sepharose were resuspended in 100 l of dephosphorylation buffer (50 mM Tris, 0, 1 mM EDTA, pH 8.5) and treated overnight at 16°C with 60 U calf intestine phosphatase (CIP, Roche).
For phosphoamino acid analyses, 2.4 ϫ 10 6 metabolically labeled HeLa cells (either [ 32 P i ] or [ 35 S]Promix) were scraped into 1-ml ice-cold CoIP buffer. Immunoprecipitation was carried out as described above using triple volumes of antiserum and protein A-Sepharose, respectively. Immune complexes were eluted three times in a total volume of 125 l sample buffer (2ϫ 50 l and 1ϫ 25 l) before being subjected to SDS-PAGE.
Phosphoamino acid analysis [two-dimensional thinlayer chromatography (2D-TLC)]
The determination of the type of phosphoamino acids was performed as described by Lötfering et al. (1999) . Briefly, either virion-associated or recombinant VP30 was metabolically labeled and purified as described above. Immune complexes were separated by SDS-PAGE and blotted onto Immobilon membranes. The phosphorylated VP30 was cut out and partially hydrolyzed using hydrochloric acid. The hydrolysates were spotted onto thinlayer chromatography plates and cochromatographed together with standard phosphoamino acids. The radioactive signals were visualized by exposing the thin-layer chromatography plates to a BioImager plate and quantified using the BioImaging Analyzer Fuji BAS-1000 with the Raytest TINA software. The standard phosphoamino acids were detected by ninhydrine.
Indirect immunofluorescence analysis
HeLa cells were cultured on glass coverslips to 50% confluence and infected with MVA-T7 as described above. At 1 h p.i., cells were transfected with plasmids encoding NP (pT-NP) and VP30 or NP and the VP30 mutants. The amount of transfected plasmid DNA encoding the VP30 mutants is given in the figure legends and was previously determined by Western blot to receive equal expression levels. At 8-12 h posttransfection, cells were fixed for 5 min with 3% paraformaldehyde (PFA) at room temperature (RT). Cells were then rinsed two times with PBS and incubated with 0.1 M glycine for 10 min at RT. Thereafter, plasma membranes were permeabilized with 0.2% of Triton X-100 for 20 min. Samples were washed again with PBS and incubated for 1 h at room temperature with the respective antibodies, as indicated in the figure legends. Subsequently, cells were washed three times with PBS and stained with the secondary antibodies for 1 h at room temperature (the secondary antibodies are indicated in the figure legends). Finally, cells were washed three times with PBS, dipped into double distilled H 2 O, covered with mounting medium, and examined using a fluorescence microscope (Axiomat, Zeiss).
Formic acid treatment
Immunoprecipitated [ 35 S]Promix-or [ 32 P i ]-labeled VP30, still bound to the protein A-Sepharose pellets was treated with 500 l of 70% formic acid for 60 h at 37°C. The formic acid was then removed by Speed Vac centrifugation, and the pellets were resuspended and dried three times with 300, 100, and 50 l double-distilled H 2 O, respectively. Samples were resuspended in sample buffer and separated by SDS-PAGE at room temperature.
Electron microscopic analysis
HeLa cells were infected with MVA-T7 and transfected with plasmids encoding NP and VP30 or a VP30 mutant.
At 16 h p.i., cells were washed once with PBS and fixed for 1 h with 4% PFA. Cells were further prepared for electron microscopy as described previously (Kolesnikova et al., 2000) .
